HCW Biologics Inc is trading at $1.15 (5.7% down) today following a regulatory filing that signaled a significant increase in share supply.
- A June 8, 2026, filing indicates a selling shareholder intends to offer up to 5.69 million shares, sparking investor concerns over potential equity dilution.
- The stock is facing downward pressure from the resulting supply overhang, underperforming despite broadly stable conditions across major market indices.